公开(公告)号：US20070160621A1

公开(公告)日：2007-07-12

申请号：US11523215

申请日：2006-09-19

申请人： William Levis ,  Frank Martiniuk

发明人： William Levis ,  Frank Martiniuk

IPC分类号： A61K39/12 ,  A61K39/00 ,  C12Q1/68 ,  G01N33/554 ,  C07H21/04 ,  C12P21/06 ,  C12N1/21 ,  C07K14/195

CPC分类号： G01N33/5695 ,  A61K39/00 ,  A61K2039/505 ,  A61K2039/6043 ,  C07K14/35 ,  C07K16/1289

摘要： The present invention is directed to heat shock proteins from Mycobacterium leprae as well as their encoding polynucleotides and vectors and host cells containing these polynucleotides. These heat shock proteins and their encoding polynucleotides are useful in detection of Mycobacterium leprae. In addition, the heat shock protein can be used as an adjuvant in a pharmaceutical composition containing an antigen to induce or enhance the immune response against the antigen. Further, the heat shock protein may be used to treat atopic conditions or as a vaccine against Mycobacterium leprae. Alternatively, the heat shock protein can be used to form a fusion protein with an antigen to induce or enhance the immune response against the antigen.

摘要翻译： 本发明涉及来自麻风分枝杆菌的热休克蛋白以及它们编码的多核苷酸和含有这些多核苷酸的载体和宿主细胞。 这些热休克蛋白及其编码多核苷酸可用于检测麻风分枝杆菌。 此外，热休克蛋白可以用作含有抗原的药物组合物中的佐剂，以诱导或增强针对抗原的免疫应答。 此外，热休克蛋白可用于治疗特应性病症或作为针对麻毒分枝杆菌的疫苗。 或者，热休克蛋白可用于与抗原形成融合蛋白以诱导或增强针对抗原的免疫应答。

公开(公告)号：US20060211766A1

公开(公告)日：2006-09-21

申请号：US11228569

申请日：2005-09-16

申请人： Leonard Kaplan ,  William Levis

发明人： Leonard Kaplan ,  William Levis

IPC分类号： A61K31/215 ,  A61K31/135 ,  A61K31/12 ,  A61K31/05

CPC分类号： A61K31/05 ,  A61K9/0014 ,  A61K31/12 ,  A61K31/135 ,  A61K31/215 ,  A61K47/10 ,  A61K47/14 ,  A61K47/26

摘要： Topical drug compositions of this invention contain delayed type contact sensitizing haptens in a unique non-flowable, non-toxic, non-volatile, anhydrous gel composition to achieve retained site application on warts and other human papilloma virus (HPV) skin infections. The preferred gelled compositions contain, but are not limited to, the sensitizing haptens, squaric acid dibutylester and diphenylcyclopropenone in optimized blends of Polysorbate 80, Isopropyl myristate uniquely gelled with Polyoxyl 40 stearate to form a penetrant of keratinized epitheliiuim of warts for direct application wherein virucidal pharlacologic action is induced by Th-1 cell mediated immune responses with resultant releases of CD4 helper T cells, CD8 killer T cells and cytokines to attack the human papilloma viruses. The commonly used vehicles with these contact sensitizers are acetone, petrolatum, or water containing emulsion creams which do not have the capacity to penetrate the keratinized wart surfaces and are therefore minimally effective in treating warts.

摘要翻译： 本发明的局部药物组合物在独特的不可流动，无毒，不挥发的无水凝胶组合物中含有延迟型接触敏化半抗原，以实现对疣和其它人乳头状瘤病毒（HPV）皮肤感染的保留位点应用。 优选的胶凝组合物包含但不限于敏化半抗原，方酸二丁酯和二苯基环丙烯酮在聚山梨醇酯80，肉豆蔻酸异丙酯的独特凝胶化与聚氧乙烯40硬脂酸酯的优化共混物中，以形成用于直接施用的疣的角质化上皮细胞的渗透剂，其中杀病毒 由Th-1细胞介导的免疫应答引起药物作用，产生CD4辅助T细胞，CD8杀伤T细胞和细胞因子的释放以攻击人乳头状瘤病毒。 具有这些接触敏化剂的常用车辆是丙酮，凡士林或含乳液乳液，其不具有穿透角质化疣表面的能力，因此在治疗疣中最不有效。

公开(公告)号：US20050260136A1

公开(公告)日：2005-11-24

申请号：US10849703

申请日：2004-05-20

申请人： Leonard Kaplan ,  William Levis

发明人： Leonard Kaplan ,  William Levis

IPC分类号： A61K49/00

CPC分类号： A61K49/0006

摘要： The compositions and methods of this invention are used to assess the level of immune competence of tested individuals based on the degree of immune response as a surrogate marker of CD4 T Cell lymphocytes as measured by the intensity of the resultant skin reaction score following controlled topical application of a unique anhydrous composition containing a contact sensitizer. The results of assessment are useful in determining appropriate treatment of immuno-compromised patients. Preferred compositions contain, but are not limited to, Diphenylcyclpropenone as a preferred embodiment of the class of contact sensitizing agents applied to the skin in an optimally prepared formulation preferably containing about 0.4% of the contact sensitizer.

摘要翻译： 本发明的组合物和方法用于基于作为CD4 T细胞淋巴细胞的替代标志物的免疫应答程度来评估测试个体的免疫能力水平，如通过受控局部应用后所得皮肤反应评分的强度所测量的 含有接触敏化剂的独特的无水组合物。 评估结果可用于确定免疫受损患者的适当治疗。 优选的组合物包含但不限于二苯基环丙烯酮，作为在优选含有约0.4％的接触敏化剂的最佳制剂制剂中施用于皮肤的接触敏化剂类的优选实施方案。